Literature DB >> 3606059

Clindamycin in a murine model of toxoplasmic encephalitis.

J M Hofflin, J S Remington.   

Abstract

We investigated the efficacy of clindamycin in a murine model of toxoplasmic encephalitis using direct intracerebral inoculation. Clindamycin reduced mortality from 40% in normal mice and 100% in cortisone-treated mice to 0% in both groups. Although we were unable to document appreciable levels of clindamycin in the brains of infected mice, the histological features of cerebral infection were markedly altered. The formation of large numbers of cysts and the intense inflammatory response seen in the brains of normal mice and the unchecked infection and tissue necrosis in the brains of cortisone-treated mice were absent in the brains of clindamycin-treated mice. Enumeration of cysts in the brains of mice 10 weeks after infection revealed a significantly lower number in the clindamycin-treated mice. Spread of infection to other organs was also decreased during clindamycin administration. These observations suggest that clindamycin may have a role in the therapy of toxoplasmic encephalitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606059      PMCID: PMC174765          DOI: 10.1128/AAC.31.4.492

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Nonspecific inhibition of tumor growth in the central nervous system: observations of intracerebral ependymoblastoma in mice with chronic Toxoplasma infection.

Authors:  F K Conley; J S Remington
Journal:  J Natl Cancer Inst       Date:  1977-09       Impact factor: 13.506

2.  Absorption, excretion and half-life of clinimycin in normal adult males.

Authors:  J G Wagner; E Novak; N C Patel; C G Chidester; W L Lummis
Journal:  Am J Med Sci       Date:  1968-07       Impact factor: 2.378

3.  Natural killer cells induced by acute and chronic toxoplasma infection.

Authors:  W E Hauser; S D Sharma; J S Remington
Journal:  Cell Immunol       Date:  1982-05-15       Impact factor: 4.868

4.  Immunohistological study of the anatomic relationship of toxoplasma antigens to the inflammatory response in the brains of mice chronically infected with Toxoplasma gondii.

Authors:  F K Conley; K A Jenkins
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

5.  Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors:  F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

6.  New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.

Authors:  D G Mack; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

7.  In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.

Authors:  S D Sharma; J M Hofflin; J S Remington
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

8.  Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients.

Authors:  W D Snider; D M Simpson; S Nielsen; J W Gold; C E Metroka; J B Posner
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

9.  Delayed hypersensitivity to Toxoplasma and unrelated antigens in Toxoplasma-infected mice: induction and elicitation of delayed-type hypersensitivity by antigen-pulsed macrophages.

Authors:  E Handman; P M Chester; J S Remington
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  A comparative study of some combined treatment regimens in acute toxoplasmosis in mice.

Authors:  E Thiermann; W Apt; A Atias; M Lorca; J Olguín
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

View more
  16 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

2.  Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures.

Authors:  D S Lindsay; B L Blagburn; J E Hall; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.

Authors:  D Israelski; J Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

6.  In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.

Authors:  C Piketty; F Derouin; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  Treatment of acute toxoplasmosis with oral clindamycin.

Authors:  K V Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

8.  Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice.

Authors:  G A Filice; C Pomeroy
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

9.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

10.  Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS.

Authors:  G Gatti; M Malena; R Casazza; M Borin; M Bassetti; M Cruciani
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.